International Phase 3 Trial Shows Survival Benefit of MM-398 Added to Standard Treatment in Metastatic Pancreatic Cancer
Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.